6YC Stock Overview
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Senzime AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.44 |
| 52 Week High | SEK 0.77 |
| 52 Week Low | SEK 0.30 |
| Beta | 0.68 |
| 1 Month Change | 31.89% |
| 3 Month Change | -9.88% |
| 1 Year Change | -23.31% |
| 3 Year Change | -73.53% |
| 5 Year Change | n/a |
| Change since IPO | -79.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6YC | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 11.5% | 1.1% | 2.5% |
| 1Y | -23.3% | -11.6% | 13.4% |
Return vs Industry: 6YC underperformed the German Medical Equipment industry which returned -11.6% over the past year.
Return vs Market: 6YC underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| 6YC volatility | |
|---|---|
| 6YC Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 6YC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6YC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 54 | Philip Siberg | www.senzime.com |
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It provides TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd.
Senzime AB (publ) Fundamentals Summary
| 6YC fundamental statistics | |
|---|---|
| Market cap | €62.56m |
| Earnings (TTM) | -€11.49m |
| Revenue (TTM) | €6.40m |
9.8x
P/S Ratio-5.4x
P/E RatioIs 6YC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6YC income statement (TTM) | |
|---|---|
| Revenue | SEK 69.86m |
| Cost of Revenue | SEK 42.80m |
| Gross Profit | SEK 27.05m |
| Other Expenses | SEK 152.51m |
| Earnings | -SEK 125.46m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 27, 2025
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 38.73% |
| Net Profit Margin | -179.60% |
| Debt/Equity Ratio | 0% |
How did 6YC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 02:20 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senzime AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Carnegie Commissioned Research |
| Oscar Stjerngren | Danske Bank |
| Klas Palin | Penser Access |